Cargando…

Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

BACKGROUND: In Italy, monoclonal antibodies targeting the CGRP pathway are subsidized for the preventive treatment of high frequency and chronic migraine (CM) in patients with a MIgraine Disability ASsessment (MIDAS) score ≥ 11. Eligibility to treatment continuation requires a ≥ 50% MIDAS score redu...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Icco, Roberto, Vaghi, Gloria, Allena, Marta, Ghiotto, Natascia, Guaschino, Elena, Martinelli, Daniele, Ahmad, Lara, Corrado, Michele, Bighiani, Federico, Tanganelli, Federica, Bottiroli, Sara, Cammarota, Francescantonio, Sances, Grazia, Tassorelli, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482180/ https://www.ncbi.nlm.nih.gov/pubmed/36115947 http://dx.doi.org/10.1186/s10194-022-01480-2

Ejemplares similares

Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
por: Sara, Bottiroli, et al.
Publicado: (2021)

Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
por: Bottiroli, Sara, et al.
Publicado: (2021)

The Virtual “Enfacement Illusion” on Pain Perception in Patients Suffering from Chronic Migraine: A Study Protocol for a Randomized Controlled Trial
por: Bottiroli, Sara, et al.
Publicado: (2022)

P008. Alexithymia and chronic migraine with medication overuse: what relationship?
por: Bottiroli, Sara, et al.
Publicado: (2015)

Oculo-vestibular signs in experimentally induced migraine attacks: an exploratory analysis
por: Corrado, Michele, et al.
Publicado: (2022)

O012. Intra-variability of the characteristics of migraine attacks
por: Viana, Michele, et al.
Publicado: (2015)

Searching for the Predictors of Response to BoNT-A in Migraine Using Machine Learning Approaches
por: Martinelli, Daniele, et al.
Publicado: (2023)

O010. Migraine aura symptoms last for more than one hour in more than one quarter of patients: results from a prospective diary-aided study
por: Viana, Michele, et al.
Publicado: (2015)

O011. Patients with “prolonged aura” do not show clinical or demographic differences from the patients with “typical aura”
por: Viana, Michele, et al.
Publicado: (2015)

P043. Hyperechogenicity of the periaqueductal gray in chronic migraine and episodic migraine as a potential marker of progressive dysfunction: preliminary results with transcranial sonography
por: Guaschino, Elena, et al.
Publicado: (2015)

EHMTI-0111. Intra-variability of migraine attacks features
por: Viana, M, et al.
Publicado: (2014)

The “care” protocol: outcome of medication overuse headache in a three year follow-up study
por: Sances, G, et al.
Publicado: (2013)

Negative Short-Term Outcome of Detoxification Therapy in Chronic Migraine With Medication Overuse Headache: Role for Early Life Traumatic Experiences and Recent Stressful Events
por: Bottiroli, Sara, et al.
Publicado: (2019)

Social cognition in chronic migraine with medication overuse: a cross-sectional study on different aspects of mentalization and social relationships
por: Bottiroli, Sara, et al.
Publicado: (2023)

EHMTI-0045. The succession of aura and headache: a prospective diary-based study
por: Viana, M, et al.
Publicado: (2014)

EHMTI-0024. The typical duration of migraine aura: a prospective diary-based study
por: Viana, M, et al.
Publicado: (2014)

EHMTI-0305. Psychological assessment of patients with chronic refractory headache: a consecutive case series
por: Galli, F, et al.
Publicado: (2014)

EHMTI-0046. The succession of aura symptoms: a prospective diary-based study
por: Viana, M, et al.
Publicado: (2014)

Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy
por: Berra, E, et al.
Publicado: (2015)

Gender Differences in the Clinical Presentation of Cluster Headache: A Role for Sexual Hormones?
por: Allena, Marta, et al.
Publicado: (2019)

The “care” protocol: the role of personality in a three-year follow-up study of medication overuse headache
por: Galli, F, et al.
Publicado: (2013)

High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients
por: Cerami, Chiara, et al.
Publicado: (2021)

Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?
por: Greco, Rosaria, et al.
Publicado: (2020)

Personality in Chronic Headache: A Systematic Review with Meta-Analysis
por: Bottiroli, Sara, et al.
Publicado: (2023)

Thalamocortical Connectivity in Experimentally-Induced Migraine Attacks: A Pilot Study
por: Martinelli, Daniele, et al.
Publicado: (2021)

Traumatic Experiences, Stressful Events, and Alexithymia in Chronic Migraine With Medication Overuse
por: Bottiroli, Sara, et al.
Publicado: (2018)

Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism
por: Di Lorenzo, Cherubino, et al.
Publicado: (2009)

Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally induced migraine attacks
por: De Icco, Roberto, et al.
Publicado: (2021)

A CARE pathway in medication–overuse headache: the experience of the Headache Centre in Pavia
por: Sances, G., et al.
Publicado: (2005)

Experimentally induced spinal nociceptive sensitization increases with migraine frequency: a single-blind controlled study
por: De Icco, Roberto, et al.
Publicado: (2020)

EHMTI-0131. Clinical features of cluster headache in women
por: Tassorelli, C, et al.
Publicado: (2014)

EUROLIGHT project: impact of primary headache disorders from a population-based study conducted in Pavia
por: Allena, M, et al.
Publicado: (2013)

EHMTI-0147. Medication overuse headache and alexithymia: a controlled study
por: Sances, G, et al.
Publicado: (2014)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021)

Who cares about migraine? Pathways and hurdles in the European region - access to care III
por: Vaghi, Gloria, et al.
Publicado: (2023)

Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings
por: Demartini, Chiara, et al.
Publicado: (2023)

Disability and migraine: MIDAS
por: D’Amico, Domenico, et al.
Publicado: (2001)

The MIDAS SDAI implementation
por: Thomas, D, et al.
Publicado: (1996)

The Effects of Intensive Neurorehabilitation on Sequence Effect in Parkinson's Disease Patients With and Without Freezing of Gait
por: Putortì, Alessia, et al.
Publicado: (2021)

Predictors of response to erenumab after 12 months of treatment
por: Baraldi, Carlo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qkgv140od92dpo9s7a0o79auf4